{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:53:47Z","timestamp":1790992427798,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02426-9","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:30:07Z","timestamp":1790991007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comorbid Cardiovascular-Liver Disease Disparities: Current Understanding and Future Directions"],"prefix":"10.1007","volume":"28","author":[{"given":"Abdelrahman","family":"Hafez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Nour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Reyad","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Zanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"De Sousa Barzon Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdelnabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elbsiony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Alsidawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"2426_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD). European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J Hepatol"},{"key":"2426_CR2","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"key":"2426_CR3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow\u2010up. Hepatology. 2015;61:1547\u201354. https:\/\/doi.org\/10.1002\/hep.27368.","journal-title":"Hepatology"},{"key":"2426_CR4","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e168\u201385. https:\/\/doi.org\/10.1161\/ATV.0000000000000153.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2426_CR5","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/hep.32743","volume":"77","author":"A Kardashian","year":"2023","unstructured":"Kardashian A, Serper M, Terrault N, Nephew LD. Health disparities in chronic liver disease. Hepatology. 2023;77:1382. https:\/\/doi.org\/10.1002\/hep.32743.","journal-title":"Hepatology"},{"key":"2426_CR6","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.3390\/jcm10215019","volume":"10","author":"M Talens","year":"2021","unstructured":"Talens M, Tumas N, Lazarus JV, Benach J, Peric\u00e0s JM. What Do We Know about Inequalities in NAFLD Distribution and Outcomes? A Scoping Review. J Clin Med. 2021;10:5019. https:\/\/doi.org\/10.3390\/jcm10215019.","journal-title":"J Clin Med"},{"key":"2426_CR7","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335. https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","journal-title":"Hepatology"},{"key":"2426_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2426_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","volume":"16","author":"NE Rich","year":"2018","unstructured":"Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, et al. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16:198\u2013e2102. https:\/\/doi.org\/10.1016\/j.cgh.2017.09.041.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2426_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jama.2021.13304","volume":"326","author":"A Flanagin","year":"2021","unstructured":"Flanagin A, Frey T, Christiansen SL, AMA Manual of Style Committee. Updated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals. JAMA. 2021;326:621\u20137. https:\/\/doi.org\/10.1001\/jama.2021.13304.","journal-title":"JAMA"},{"key":"2426_CR11","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461\u20135. https:\/\/doi.org\/10.1038\/ng.257.","journal-title":"Nat Genet"},{"key":"2426_CR12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybj\u00e6rg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352\u20136. https:\/\/doi.org\/10.1038\/ng.2901.","journal-title":"Nat Genet"},{"key":"2426_CR13","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1097\/TP.0000000000004964","volume":"108","author":"EC Becker","year":"2024","unstructured":"Becker EC, Siddique O, O\u2019Sullivan DM, Dar W, Einstein M, Morgan G, et al. Disparities in Liver Transplantation for Nonalcoholic Steatohepatitis in Women. Transplantation. 2024;108:e181. https:\/\/doi.org\/10.1097\/TP.0000000000004964.","journal-title":"Transplantation"},{"key":"2426_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320622","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020. https:\/\/doi.org\/10.1136\/gutjnl-2020-320622.","journal-title":"Gut"},{"key":"2426_CR15","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1038\/s41598-021-83367-x","volume":"11","author":"S-R Lee","year":"2021","unstructured":"Lee S-R, Han K-D, Choi E-K, Oh S, Lip GYH. Nonalcoholic fatty liver disease and the risk of atrial fibrillation stratified by body mass index: a nationwide population-based study. Sci Rep. 2021;11:3737. https:\/\/doi.org\/10.1038\/s41598-021-83367-x.","journal-title":"Sci Rep"},{"key":"2426_CR16","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","volume":"71","author":"TG Simon","year":"2022","unstructured":"Simon TG, Roelstraete B, Hagstr\u00f6m H, Sundstr\u00f6m J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71:1867\u201375. https:\/\/doi.org\/10.1136\/gutjnl-2021-325724.","journal-title":"Gut"},{"key":"2426_CR17","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jhep.2017.08.024","volume":"67","author":"DH Sinn","year":"2017","unstructured":"Sinn DH, Kang D, Jang HR, Gu S, Cho SJ, Paik SW, et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. J Hepatol. 2017;67:1274\u201380. https:\/\/doi.org\/10.1016\/j.jhep.2017.08.024.","journal-title":"J Hepatol"},{"key":"2426_CR18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/apt.15660","volume":"51","author":"JB Henson","year":"2020","unstructured":"Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51:728\u201336. https:\/\/doi.org\/10.1111\/apt.15660.","journal-title":"Aliment Pharmacol Ther"},{"key":"2426_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4291\/wjgp.v9.i1.28","volume":"9","author":"E Tsiompanidis","year":"2018","unstructured":"Tsiompanidis E, Siakavellas SI, Tentolouris A, Eleftheriadou I, Chorepsima S, Manolakis A, et al. Liver cirrhosis-effect on QT interval and cardiac autonomic nervous system activity. WJGP. 2018;9:28\u201336. https:\/\/doi.org\/10.4291\/wjgp.v9.i1.28.","journal-title":"WJGP"},{"key":"2426_CR20","doi-asserted-by":"publisher","first-page":"9420","DOI":"10.3390\/ijms21249420","volume":"21","author":"JI Fortea","year":"2020","unstructured":"Fortea JI, Puente \u00c1, Cuadrado A, Huelin P, Pell\u00f3n R, Gonz\u00e1lez S\u00e1nchez FJ, et al. Congestive Hepatopathy IJMS. 2020;21:9420. https:\/\/doi.org\/10.3390\/ijms21249420.","journal-title":"Congestive Hepatopathy IJMS"},{"key":"2426_CR21","doi-asserted-by":"publisher","first-page":"862330","DOI":"10.3389\/fcvm.2022.862330","volume":"9","author":"F Hamberger","year":"2022","unstructured":"Hamberger F, Legchenko E, Chouvarine P, Mederacke YS, Taubert R, Meier M, et al. Pulmonary Arterial Hypertension and Consecutive Right Heart Failure Lead to Liver Fibrosis. Front Cardiovasc Med. 2022;9:862330. https:\/\/doi.org\/10.3389\/fcvm.2022.862330.","journal-title":"Front Cardiovasc Med"},{"key":"2426_CR22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28:528\u201362. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010.","journal-title":"Endocr Pract"},{"key":"2426_CR23","doi-asserted-by":"publisher","unstructured":"Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, et al. ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online 2026 March 13. https:\/\/doi.org\/10.1161\/CIR.0000000000001423","DOI":"10.1161\/CIR.0000000000001423"},{"key":"2426_CR24","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675\u201385. https:\/\/doi.org\/10.1056\/NEJMoa0907929.","journal-title":"N Engl J Med"},{"key":"2426_CR25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(14)61933-4.","journal-title":"Lancet"},{"key":"2426_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390:497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"key":"2426_CR27","unstructured":"U.S. Food and Drug Administration. FDA Approves First Treatment for Patients With Liver Scarring Due to Fatty Liver Disease. 2024 March 14. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease. Accessed 13 Sept 2026."},{"key":"2426_CR28","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384:1113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2028395.","journal-title":"N Engl J Med"},{"key":"2426_CR29","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392:2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"key":"2426_CR30","unstructured":"Food US, Administration D. FDA Approves Treatment for Serious Liver Disease Known as MASH. 2025. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash.\u00a0 13\u00a0Accessed Sept 2026."},{"key":"2426_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391:299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"key":"2426_CR32","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"key":"2426_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"key":"2426_CR34","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"key":"2426_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"key":"2426_CR36","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"2426_CR37","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377:644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med"},{"key":"2426_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"key":"2426_CR39","doi-asserted-by":"publisher","first-page":"e0024","DOI":"10.1097\/HC9.0000000000000024","volume":"7","author":"RK Fox","year":"2023","unstructured":"Fox RK, Chu JN, Goldman ML, Islam KB, Brandman D. Prospective study of a case-finding algorithm to detect NAFLD with advanced fibrosis in primary care patients. Hepatol Commun. 2023;7:e0024. https:\/\/doi.org\/10.1097\/HC9.0000000000000024.","journal-title":"Hepatol Commun"},{"key":"2426_CR40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.amjms.2024.07.028","volume":"368","author":"JFG Bobo","year":"2024","unstructured":"Bobo JFG, Keith BA, Marsden J, Zhang J, Schreiner AD. Patterns of GI Specialty Referral for Primary Care Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Am J Med Sci. 2024;368:455\u201361. https:\/\/doi.org\/10.1016\/j.amjms.2024.07.028.","journal-title":"Am J Med Sci"},{"key":"2426_CR41","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","volume":"146","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, et al. Life\u2019s Essential 8: Updating and Enhancing the American Heart Association\u2019s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation. 2022;146:e18\u201343. https:\/\/doi.org\/10.1161\/CIR.0000000000001078.","journal-title":"Circulation"},{"key":"2426_CR42","unstructured":"Novo Nordisk. Wegovy\u00ae (semaglutide) Cost, Coverage, & Savings Resources. NovoCare. https:\/\/www.novocare.com\/patient\/medicines\/wegovy.html. Accessed 13 Sept 2026."},{"key":"2426_CR43","unstructured":"ClinicalTrials.gov. A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH). NCT03900429. https:\/\/clinicaltrials.gov\/study\/NCT03900429. Accessed 13 Sept 2026."},{"key":"2426_CR44","unstructured":"ClinicalTrials.gov. Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (ESSENCE). NCT04822181. https:\/\/clinicaltrials.gov\/study\/NCT04822181. Accessed 13 Sept 2026."},{"key":"2426_CR45","unstructured":"Eli Lilly and Company. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes). ClinicalTrials.gov identifier: NCT07165028. https:\/\/trials.lilly.com\/en-US\/trial\/651596. Accessed 13 Sept 2026."}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02426-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02426-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02426-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:30:09Z","timestamp":1790991009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02426-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2426"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02426-9","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"26 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Chadi Ayoub reports a stipend received as Section Editor from Circulation: Cardiovascular Imaging, outside the submitted work. The remaining authors have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"102"}}